TScan Therapeutics’ (TCRX) “Buy” Rating Reaffirmed at Needham & Company LLC

Needham & Company LLC reissued their buy rating on shares of TScan Therapeutics (NASDAQ:TCRX) in a research report released on Tuesday morning,Benzinga reports. The brokerage currently has a $9.00 price objective on the stock.

TCRX has been the subject of several other research reports. Barclays decreased their target price on shares of TScan Therapeutics from $14.00 to $3.00 and set an “overweight” rating for the company in a research report on Friday, March 7th. Morgan Stanley reissued an “overweight” rating and issued a $10.00 price objective on shares of TScan Therapeutics in a report on Friday, March 14th. HC Wainwright reiterated a “buy” rating and set a $15.00 price target on shares of TScan Therapeutics in a research report on Thursday, March 6th. Finally, Wedbush reissued an “outperform” rating and issued a $7.00 price target on shares of TScan Therapeutics in a research note on Wednesday, March 5th. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $9.33.

TScan Therapeutics Stock Performance

Shares of TCRX stock opened at $1.18 on Tuesday. The company has a quick ratio of 9.56, a current ratio of 9.56 and a debt-to-equity ratio of 0.13. The business has a 50 day moving average of $1.85 and a two-hundred day moving average of $3.33. The company has a market cap of $66.78 million, a P/E ratio of -1.11 and a beta of 1.09. TScan Therapeutics has a 52 week low of $1.06 and a 52 week high of $9.69.

TScan Therapeutics (NASDAQ:TCRX) last issued its quarterly earnings data on Wednesday, March 5th. The company reported ($0.29) EPS for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.02). TScan Therapeutics had a negative return on equity of 58.72% and a negative net margin of 1,188.88%. The company had revenue of $0.67 million for the quarter, compared to the consensus estimate of $1.43 million. As a group, analysts anticipate that TScan Therapeutics will post -1.12 EPS for the current year.

Institutional Trading of TScan Therapeutics

Several institutional investors have recently modified their holdings of TCRX. abrdn plc grew its holdings in TScan Therapeutics by 137.8% during the fourth quarter. abrdn plc now owns 883,704 shares of the company’s stock worth $2,686,000 after acquiring an additional 512,049 shares during the period. State Street Corp grew its stake in shares of TScan Therapeutics by 24.4% in the 3rd quarter. State Street Corp now owns 756,499 shares of the company’s stock worth $3,767,000 after purchasing an additional 148,414 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of TScan Therapeutics by 108.5% in the 4th quarter. Dimensional Fund Advisors LP now owns 280,028 shares of the company’s stock worth $851,000 after purchasing an additional 145,731 shares in the last quarter. Lynx1 Capital Management LP lifted its stake in TScan Therapeutics by 2.5% during the fourth quarter. Lynx1 Capital Management LP now owns 5,357,347 shares of the company’s stock valued at $16,286,000 after purchasing an additional 132,747 shares during the last quarter. Finally, Tang Capital Management LLC bought a new stake in TScan Therapeutics during the fourth quarter worth approximately $358,000. Institutional investors and hedge funds own 82.83% of the company’s stock.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.